TEST SCHEDULES
 


Cellular

Flow Cytometry

Immunohistochemistry

 

Sub Cellular

Classic Cytogenetics

Digital Image Analysis

 

Sub Chromosomal

Molecular Cytogenetics
                 FISH

 

Molecular

Molecular Genetics-
                 PCR

  
   

Flow Cytometry Testing

Flow cytometric analysis is a quantitative technique for measuring multiple cell parameters, including cell surface antigens and DNA content. Analyses can be performed on peripheral blood, bone marrow, and/or solid tissue. The technique is most commonly used to assess immunologic status and oncology.

Laboratory services include lymphocyte immunophenotyping to monitor the immune status of HIV-infected persons; cellular phenotypes including cell surface, cytoplasmic, and nuclear markers that are cell-lineage specific used in the classification of leukemias and lymphomas; and DNA content and cell cycle analysis.

Lymphoproliferative / leukemic panels are important in identifying large granular lymphocytosis, follicular lymphoma, hairy cell leukemia, B-cell CLL, mantle cell lymphoma. Reflex testing to molecular genetics for confirming inherent molecular endpoints is routine.

 
 
 
 

Download our Tests  -- Organized by how you use them

Alphabetical Test List (28k)  or by Test #
    - with reference #

Test list by the type of disease testing (155k)
    - with reference #, Test Type and Description

Tests Details (425k)

    - alphabetical with reference #, Test Type, Includes, CPT Codes, Descriptions, and Disease/Specialty cross reference.

We are happy to take recommendations on how our test lists could be organized to better communicate how we might solve your patients' needs.  Call us.

Tests By Type
ref# Test Type Test Name CPT code Includes Description Clinical Significance Specimen
99 Flow Cytometry Absolute CD4 (T4) Panel 88184(1) CD4 (T4) This assay is designed for enumerating the absolute cell counts of helper T-cells in whole blood.
 
 
100 Flow Cytometry CD34 Quantitation 88184(1) CD34 This assay is used to quantify CD34-positive cells stem cells in the peripheral blood of patients awating stem cell harvest for autologus stem cell transplantation. CD34 counts are determined by a modified version of the ISHAGE protocol using CD45, CD34, and light scatter properties to identify the stem cell population. Viability of the stem cells is also assessed using a DNA binding dye 7-AAD. The absolute number of CD34-positive cells per microliter of peripheral blood is determined using absolute counting beads. pbsct
 
101 Flow Cytometry Chronic Granulomatous Disease (CGD) * Time Test 88184(1), 88185(1), 88187(1) Neutrophil Oxidative Burst Assay (DNR), Interpretation CGD is an inherited disorder with both X-linked and autosomal recessive forms. Patients are susceptible to infections. Early diagnosis is important for prophylactic therapy. Using a flow cytometric based assay, patients can be identified based on functional deficiencies of their neutrophils to oxidize dihydrorhodamine 123 (DHR). positive for Chronic Granulomatous Disease
 
116 Flow Cytometry cIg / DNA ploidy 88184(2), 88182(1), 88187 k, l, DNA content Neoplastic plasma cells express little or no surface immunoglobulin, cytoplasmic k and l light chain expression in permeabilized cells is used to look for clonality. Within clonally restricted cells, DNA content can be determine which is helpful in identifying hyperdiploid forms of plasma cell dyscrasias.
 		 Peripheral Blood, Bone Marrow
102 Flow Cytometry DNA Content / Ploidy Solid Tumor and Hematologic conditions 88182(1) DNA Analysis and proliferative phase analysis DNA content is frequently abnormal in solid tumors (breast, colorectal, prostate) and hematologic conditions (acute leukemias, myeloma)
 
 
103 Flow Cytometry Immunodeficiency Panel 88184(1), 88185(5), 88187(1) CD3, CD4, CD8, CD19, CD45, CD56+16 & Interpretation This is a comprehensive evaluation of circulating levels of T-cells, B-cells, and NK-cells used in the evaluation of immunodeficient conditions.
 
 
104 Flow Cytometry Immunodeficiency Screen, Congenital 88184(1), 88185(8), 88187(1) CD2, CD3, CD4, CD8, CD19, CD45-RO, CD45-RA, HLA-DR, NK cell & Interpretation This profile evaluates the individual for inherited immunodeficiencies. T-cells, B-cells, and NK-cells are evaluated. Immunodeficiencies that exhibit immunophenotypic abnormalities include DiGeorge syndrome, X-linked hypgammaglobulinemia, and severe combined immunodeficiency.
 
 
118 Flow Cytometry Immunodeficiency Screen, Congenital, B-cell 88184(1), 88185(5), 88187(1) CD19, CD45, HLA-DR, IgG, IgA & Interpretation This assay evaluates circulating B-cells (CD19), their surface immunoglobulins (total Ig, IgG, IgD, IgM, and IgA), and a common HLA class II antigen. The B-Cell Immunodeficiency Profile measures circulating B-cells (CD19), their surface immunoglobulins (Total Ig, IgG, IgD, IgM and IgA), and a common HLA class II antigen. The percentage of lymphocytes expressing CD19, various immunoglobulin fractions, and HLA-DR may be altered in certain immunologic abnormalities. For example, HLA-DR is absent on B-cells in the bare lymphocyte syndrome (MHC Class II Deficiency). In severe combined immunodeficiency, the percentage of B-cells is increased; while in X-linked agammaglobulinemia, the B-cell percentage is decreased. IgM is expressed early in B-cell ontogeny, whereas, IgD is expressed along with IgM in immunocompetent, mature B-cells.
 
105 Flow Cytometry Immunophenotyping dependent on number of markers utilized Various Markers dependant on clinical signs and symptoms Panels dependent upon disease of interest.
 
 
106 Flow Cytometry Leukemia Phenotyping Panel (comprehensive) 88184(1), 88185(20), 88189(1) CD2, CD5, CD7, CD10, CD11b, CD13, CD14, CD15, CD19, CD33, CD34, CD38, CD45, CD56, CD61, CD71, CD79A, CD11, HLA-DR, MPO, TdT (Terminal deoxynucleotidyl transferase) & Interpretation The acute leukemia panel is designed to determine whether blasts are myeloid or lymphoid in origin, and to classify the cells within the myeloid/monocytic or lymphoid lineages. The analysis is performed unsing four- and five-color immunophenotyping.
 
 
107 Flow Cytometry Leukocyte Adhesion Deficiency (LAD) 88184(1), 88185(3), 88187(1) CD11a, CD11b, CD11c, CD18, Interpretation This assay measures the neutrophil receptors required for surface adhesion and phagocytosis. Normal neutrophils exhibit CD11b, CD15, CD16, CD18, CD11c, and CD11a. CD18 is decreased or absent in LAD, type I. CD15 is decreased or absent in LAD, type II. These disorders are usually detected in infancy or childhood and result in recurrent infections.
 
 
110 Flow Cytometry Lymphocyte Subsets (T helper/Suppressor Panel) 88184(1), 88185(2), 88187(1) CD3, CD4, CD8 This assay measures T-cells (CD3) and T-cell subsets (CD4, CD8). Levels are established by CDC for categorizing HIV-related clinical conditions.
 
 
111 Flow Cytometry Lymphocyte Transplantation Phenotype 88184(1), 88185(4), 88187(1) CD2, CD3, CD4, CD8, TCRab, TCRgd CD3-positive T-cells are evaluated in the presence of normal T-cell receptor heterodimers. Immunosuppressive therapy with anti-lymphocyte medications (such as ATG or OKT3) can be monitored with this assay
 
 
109 Flow Cytometry Lymphocytosis / Lymphoma Panel (abbreviated) 88184(1), 88185(8), 88189(1) CD5, CD10, CD13, CD14, CD19, CD34, CD45, KAPPA, LAMBDA & Interpretation The lymphoma panel is designed to characterize lymphoproliferative disorders, which are usually comprised of mature B or T cells. Immunoglobulin light chain restriction of either k or l is usually confirmatory of a monoclonal B-cell malignancy.
 
 
108 Flow Cytometry Lymphocytosis / Lymphoma Panel (comprehensive) 88184(1), 88185(25), 88189(1) CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD19, CD20, CD22, CD23, CD24, CD25, CD30, CD38, CD43, CD45, CD52, CD56, CD79b, CD103, CD138, FMC7, ZAP70, KAPPA, LAMBDA, & Interpretation Based on results of the abbreviated panel, additional B or T-cell antibodies may be added to arrive at a final diagnosis and further classify the lymphoproliferative disorder. Antibodies unique for hairy cell leukemia (CD11c/CD25/CD103), mantle cell lymphoma (CD23), CD56 (LGL/NK cells), and CLL (FMC7) are examples of included in the comprehensive panel. This test can be ordered to help with the clinical management of patients with established diagnoses of CLL. It is not appropriate to order this test to screen for CLL, help establish a diagnosis of CLL, or for patients with other types of lymphoproliferative disorders or leukemias besides CLL.
 
112 Flow Cytometry Myelodysplasia Screen 88184(1), 88185(7), 88187(1) CD11b, CD13, CD15, CD16, CD33, CD34, CD45, CD56 & Interpretation This assay is designed as an adjunct in the diagnosis of myelodysplastic versus myeloproliferative syndromes. The identification of significant immunophenotypic abnormalities among the myeloid blasts, maturing myeloid cells, and/or monocytes is these cases is regarded as evidence supporting the presence of a stem cell neoplasm. Note: to confirm the diagnosis of myelodysplasia or CML, molecular and cytogenetic testing may be required.
 
 
113 Flow Cytometry Myeloma / Plasma cell dyscrasia Panel 88184(1) 88185(12), 88188(1) CD2, CD5, CD7, CD10, CD19, CD20, CD22, CD38, CD45, CD56, CD138, KAPPA, LAMBDA & Interpretation This assay is designed to identify neoplastic plasma cells. Plasma cells exhibit a unique immunophenotype that is easily distinguished using this panel.
 
 
114 Flow Cytometry Paroxysmal Nocturnal Hemoglobinuria (PNH) Screen 88184(1), 88185(3), 88187(1) CD55, CD59 & Interpretation This assay evaluates the presence/absence of glycosylphosphatidylinositol (GPI) linkage of certain cell surface proteins linked to this disease, a rare, acquired clonal stem cell disorder due to a mutation in the hemaotpietic stem cell that causes partial or complete loss of GPI-linked proteins. The assay examines CD55/CD59 on erythrocytes and monocytes/neutrophils. Because the GPI-linked proteins are examined on mature erythrocytes, moncytes, and enutrophiles, the assay is best performed on peripheral blood rather than bone marrow.
 
 
115 Flow Cytometry Therapeutic Antibody Monitoring 88184(1), 88185(3),88187(1) CD20, CD22, CD33, CD52 & Interpretation Monitoring of cells remaining post-targeted immunomodulative therapy (i.e. CD20-Rituxan, CD52-Campath, CD33-Myelotarg)